Table 4.
Cost drivers for the fracture treatment cost by multivariable regression analysis a
| Coefficients | 95% CI Lower |
95% CI Upper |
P value | |
|---|---|---|---|---|
| Gender (base = male) | 1.08 | 1.00 | 1.16 | < 0.05 |
| Age (base = 50–59) | ||||
| 60–69 | 1.20 | 1.01 | 1.42 | < 0.05 |
| 70–79 | 1.26 | 1.07 | 1.48 | < 0.01 |
| 80–89 | 1.26 | 1.07 | 1.48 | < 0.01 |
| 90- | 1.12 | 0.93 | 1.35 | |
| Treatment period (month) | 1.05 | 1.05 | 1.06 | < 0.01 |
| Fracture category (base = hip) | ||||
| Vertebral | 0.20 | 0.19 | 0.22 | < 0.01 |
| NHNV | 0.26 | 0.24 | 0.28 | < 0.01 |
| Comorbidities | ||||
| GI diseases | 1.01 | 0.95 | 1.08 | 0.66 |
| Hypertension | 1.13 | 1.06 | 1.20 | < 0.01 |
| Other functional intestinal disorder | 1.03 | 0.97 | 1.09 | 0.40 |
| Dorsalgia | 0.90 | 0.85 | 0.96 | < 0.01 |
| Disorders of lipoprotein metabolism and other lipidemia | 1.00 | 0.94 | 1.06 | 0.98 |
| Sleep disorders | 1.03 | 0.97 | 1.10 | 0.29 |
| Diabetes | 0.97 | 0.91 | 1.04 | 0.38 |
| Osteoarthritis of knee | 1.01 | 0.94 | 1.07 | 0.83 |
| Angina pectoris | 1.05 | 0.98 | 1.13 | 0.20 |
| Heart failure | 0.95 | 0.88 | 1.03 | 0.19 |
| Disorder of refraction and accommodation | 0.86 | 0.80 | 0.93 | < 0.01 |
| Iron deficiency anemia | 1.15 | 1.07 | 1.25 | < 0.01 |
| COPD | 0.91 | 0.84 | 1.00 | < 0.05 |
| Chronic kidney disease | 0.93 | 0.82 | 1.05 | 0.24 |
| Thyrotoxicosis | 1.11 | 0.91 | 1.39 | 0.32 |
| Hypofunction and other disorders of the pituitary gland | 1.09 | 0.68 | 1.94 | 0.73 |
| Primary hyperparathyroidism | 2.08 | 0.88 | 6.81 | 0.15 |
| Cushing’s syndrome | 0.46 | 0.14 | 3.27 | 0.30 |
an = 12,898